This site is intended for healthcare professionals

Phase III ASCENT study of Trodelvy met its primary endpoint of progression-free survival for triple negative breast cancer.- Immunomedics Inc.

Read time: 1 mins
Last updated:16th Mar 2021
Published:12th Jul 2020
Condition: Breast Cancer Triple Neg
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest